New water-soluble duocarmycin derivatives: Synthesis and antitumor activity of A-ring pyrrole compounds bearing β-heteroarylacryloyl groups

Journal of Medicinal Chemistry

Volumn 42, Issue 4, 1999, Pages 669-676

  Amishiro, Nobuyoshi ^a   Nagamura, Satoru ^a   Kobayashi, Eiji ^a   Gomi, Katsushige ^a   Saito, Hiromitsu ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DUOCARMYCIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; DRUG MECHANISM; DRUG POTENCY; DRUG SOLUBILITY; HELA CELL; MOUSE; NONHUMAN; SARCOMA; STRUCTURE ACTIVITY RELATION;

ADENOCARCINOMA; ANIMALS; BLOOD PLATELETS; DRUG SCREENING ASSAYS, ANTITUMOR; HELA CELLS; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PYRROLES; SARCOMA 180; STOMACH NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS;

EID: 0033602254     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980559y     Document Type: Article

References (73)

1. (a) Takahashi, I.; Takahashi, K.; Ichimura, M.; Morimoto, M.; Asano, K.; Kawamoto, I.; Tomita, F.; Nakano, H. Duocarmycin A, a New Antibiotic from Streptomyces. J. Antibiot. 1988, 41, 1915-1917.
2. (b) Yasuzawa, T.; Iida, T.; Muroi, K.; Ichimura, M.; Takahashi, K.; Sano, H. Structure of Duocarmycins, Novel Antitumor Antibiotics Produced by Streptomyces sp. Chem. Pharm. Bull. 1988, 36, 3728-3731.
3. (c) Ichimura, M.; Muroi, K.; Asano, K.; Kawamoto, I.; Tomita, F.; Morimoto, M.; Nakano, H. DC89-A1, A New Antibiotic from Streptomyces. J. Antibiot. 1988, 41, 1285-1288.
4. (d) Ogawa, T.; Ichimura, M.; Katsumata, S.; Morimoto, M.; Takahashi, K. New Antitumor Antibiotics, Duocarmycin B1 and B2. J. Antibiot. 1989, 42, 1299-1301.
5. (e) Ichimura, M.; Ogawa, T.; Takahashi, K.; Kobayashi, E.; Kawamoto, I.; Yasuzawa, T.; Takahashi, I.; Nakano, H. Duocarmycin SA, a New Antitumor Antibiotic from Streptomyces sp. J. Antibiot. 1990, 43, 1037-1038.
6. (f) Ichimura, M.; Ogawa, T.; Katumata, S.; Takahashi, K.; Takahashi, I.; Nakano, H. Duocarmycins, New Antitumor Antibiotics Produced by Streptomyces; Producing Organisms and Improved Production. J. Antibiot. 1991, 44, 1045-1053.
7. (g) Yasuzawa, T.; Saitoh, Y.; Ichimura, M.; Takahashi, I.; Sano, H. Structure of Duocarmycin SA, a Potent Antitumor Antibiotic. J. Antibiot. 1991, 44, 445-447.
8. (h) Yasuzawa, T.; Muroi, K.; Ichimura, M.; Takahashi, I.; Takahashi, K.; Sano, H.; Saitoh, Y. Duocarmycins, Potent Antitumor Antibiotics by Streptomyces sp. Structure and Chemistry. Chem. Pharm. Bull. 1995, 43, 378-391.
9. Gomi, K.; Kobayashi, E.; Miyoshi, K.; Ashizawa, T.; Okamoto, A.; Ogawa, T.; Katsumata, S.; Mihara, A.; Okabe, M.; Hirata, T. Anticellular and Antitumor Activity of Duocarmycins, Novel Antitumor Antibiotic. Jpn. J. Cancer Res. 1992, 52, 113-120.
10. A number of reviews on the duocarmycins are available from the following: (a) Boger, D. L. Duocarmycins: A New Class of Sequence Selective DNA Minor Groove Alkylating Agents. CHEMTRACTS: Org. Chem. 1991, 4, 329-349.
11. (b) Boger, D. L. The Duocarmycins: Synthesis and Mechanistic Studies. Acc. Chem. Res. 1995, 28, 20-29.
12. (c) Boger, D. L.; Johnson, D. S. CC-1065 and Duocarmycins: Unraveling the Keys to A New Class of Naturally Derived DNA Alkylating Agents. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 3642-3649.
13. (d) Boger, D. L.; Johnson, D. S. CC-1065 and the Duocarmycins: Understanding their Biological Function through Mechanistic Studies. Angew. Chem., Int. Ed. Engl. 1996, 35, 1438-1474.
14. (a) Sugiyama, H.; Hosoda, M.; Saito, I.; Asai, A.; Saito, H. Covalent Alkylation of DNA with Duocarmycin A. Identification of Abasic Site Structure. Tetrahedron Lett. 1990, 31, 7197-7200.
15. (b) Boger, D. L.; Ishizaki, T.; Zarrinmayeh, H. Synthesis and Preliminary Evaluation of Agents Incorporating the Phamacophore of the Duocarmycin/Pyrindamycin Alkylation Subunit: Identification of the CC-1065/Duocarmycin Common Pharmacophore. J. Org. Chem. 1990, 55, 4499-4502.
16. (c) Boger, D. L.; Ishizaki, T.; Zarrinmayeh, H.; Munk, S. A.; Kitos, P. A.; Suntornwat, O. Duocarmycin-Pyrindamycin DNA Alkylation Properties and Identification, Synthesis, and Evaluation of Agents Incorporating the Pharmacophore of the Duocarmycin-Pyrindamycin Alkylation Subunit. Identification of the CC-1065-Duocarmycin Common Pharmacophore. J. Am. Chem. Soc. 1990, 112, 8961-8971.
17. (d) Boger, D. L.; Ishizaki, T.; Zarrinmayeh, H. Isolation and Characterization of the Duocarmycin-adenine DNA Adduct. J. Am. Chem. Soc. 1991, 113, 6645-6649.
18. (e) Sugiyama, H.; Ohmori, K.; Chan, K. L.; Hosoda, M.; Asai, A.; Saito, H.; Saito, I. A Novel Guanine N3 Alkylation by Antitumor Antibiotic Duocarmycin A. Tetrahedron Lett. 1993, 34, 2179-2182.
19. (f) Boger, D. L.; Johnson, D. S.; Yun, W. (+)-and ent-(-)-Duocarmycin SA and (+)-and ent-(-)-N-Boc-DSA DNA Alkylation Properties. Alkylation Site Models that Accommodate the Offset AT-rich Adenine N3 Alkylation Selectivity of the Enantiomeric Agents. J. Am. Chem. Soc. 1994, 116, 1635-1656.
20. (a) Hanka, L. J.; Dietz, A.; Gerpheide, S. A.; Kuentzel, S. L.; Martin, D. G. CC-1065 (NSC-298223), a New Antitumor Antibiotic. Production, in vitro Biological Activity, Microbiological Assays, and Taxonomy of the Producing Microorganism. J. Antibiot. 1978, 31, 1211-1217.
21. (b) Martin, D. G.; Chidester, C. G.; Duchamp, D. J.; Mizsak, S. A. Structure of CC-1065 (NSC-298223), a New Antitumor Antibiotic. J. Antibiot. 1980, 33, 902-903.
22. (c) Reynolds, V. L.; McGovren, J. P.; Hurley, L. H. The Chemistry, Mechanism of Action and Biological Properties of CC-1065, a Potent Antitumor Antibiotic. J. Antibiot. 1986, 39, 319-334.
23. (a) Hurley, L. H.; Reynolds, V. L.; Swenson, D. H.; Petzold, G. L.; Scahill, T. A. Reaction of the Antitumor Antibiotic CC-1065 with DNA: Structure of A DNA Adduct with DNA Sequence Specificity. Science 1984, 226, 843-844.
24. (b) Reynolds, V. L.; Molineaux, I. J.; Kaplan, D. J.; Swensen, D. H.; Hurley, L. H. Reaction of the Antitumor Antibiotic CC-1065 with DNA. Location for the Site of Thermally Induced Strand Breakage and Analysis of DNA Sequence Specificity. Biochemistry 1985, 24, 6228-6237.
25. (c) Tang, M. S.; Lee, C. S.; Doisy, R.; Ross, L.; Needham-VanDevanter, D. R.; Hurley, L. H. Recognition and Repair of the CC-1065-(N3-adenine)-DNA Adduct by the UVRABC Nuclease. Biochemistry 1988, 27, 893-901.
26. (a) Nagamura, S.; Asai, A.; Kanda, Y.; Kobayashi, E.; Gomi, K.; Saito, H. Synthesis and Antitumor Activity of Duocarmycin Derivatives: Modification of Segment A Duocarmycin B2. Chem. Pharm. Bull. 1996, 44, 1723-1730.
27. (b) Kobayashi, E.; Okamoto, A.; Asada, M.; Okabe, M.; Nagamura, S.; Asai, A.; Saito, H.; Gomi, K.; Hirata T. Characteristics of Antitumor Activity of KW-2189, a Novel Water-soluble Derivative of Duocarmycin, Against Murine and Human Tumors. Cancer Res. 1994, 54, 2404-2410.
28. (c) Asai, A.; Nagamura, S.; Saito, H. A Novel Property of Duocarmycin and its Analogues for Covalent Reaction with DNA. J. Am. Chem. Soc. 1994, 116, 4171-4177.
29. (d) Nagamura, S.; Kobayashi, E.; Gomi, K.; Saito, H. Studies on the Active Metabolite (DU-86) of KW-2189, a Novel Derivative of Duocarmycin. Bioorg. Med. Chem. Lett. 1996, 6, 2147-2150.
30. Nagamura, S.; Kanda, Y.; Kobayashi, E.; Gomi, K.; Saito, H. Synthesis and Antitumor Activity of Duocarmycin Derivatives. Chem. Pharm. Bull. 1995, 43, 1530-1535.
31. 2: Enhanced Functional Analogues of (+)-CC-1065. A Critical Appraisal of a Proposed Relationship between Electrophile Reactivity, DNA Binding Properties, and Cytotoxic Potency. Tetrahedron Lett. 1990, 31, 793-796.
32. (b) Boger, D. L.; Mesini, P.; Tarby, C. M. Chemical and Structural Comparison of N-Boc-CBQ and N-Boc-CBI: Identification and Structural Origin of an Unappreciated but Productive Stability of the CC-1065 and Duocarmycin SA Alkylation Subunits. J. Am. Chem. Soc. 1994, 116, 6461-6462.
33. (c) Boger, D. L.; McKie, J. A.; Han, N.; Taby, C. M.; Riggs, H. W.; Kitos, P. A. A Hammett Correlation for CC-1065 and Duocarmycin Analogues: Magnitude of Substituent Electronic Effects on Functional Reactivity. Bioorg. Med. Chem. Lett. 1996, 6, 659-664.
34. (d) Boger, D. L.; Goldberg, J.; McKie, J. A. A Comparative Study of the Solvolysis Reactivity, Regioselectivity, and Stereochemistry of the Duocarmycin A and SA Alkylation Subunits. Bioorg. Med. Chem. Lett. 1996, 6, 1955-1960.
35. (e) Boger, D. L.; Boyce, C.; Johnson, D. S. pH Dependence of the Rate of DNA Alkylation for (+)-Duocarmycin SA and (+)-CBI-TMI. Bioorg. Med. Chem. Lett. 1997, 7, 233-238.
36. (a) Nagamura, S.; Kobayashi, E.; Gomi, K.; Saito, H. Synthesis and Antitumor Activity of Duocarmycin Derivatives: A-ring Pyrrole Analogues of Duocarmycin B2. Bioorg. Med. Chem. 1996, 4, 1379-1391.
37. (b) Ogasawara, H.; Nishio, K.; Takeda, Y.; Ohmori, T.; Kubota, N.; Funayama, Y.; Ohira, T.; Kuraishi, Y.; Isogai, Y.; Saijo, N. A Novel Antitumor Antibiotics, KW-2189 is Activated by Carboxyl Esterase and Induces DNA Strand Breaks in Human Small Cell Lung Cancer Cells. Jpn. J. Cancer Res. 1994, 54, 418-425.
38. 3 Cells. Jpn. J. Cancer Res. 1994, 85, 1304-1311.
39. (d) Ogasawara, H.; Nishio, K.; Kanzawa, F.; Lee, Y. S.; Funayama, Y.; Ohmori, T.; Kuraishi, Y.; Isogai, Y.; Saijo, N. Intracellular Carboxyl Esterase Activity is A Determinant of Cellular Sensitivity to the Antineoplastic Agent KW-2189 in Cell lines Resistant to Cisplatin and CPT-11. Jpn. J. Cancer Res. 1995, 55, 124-129.
40. (e) Ogasawara, H.; Nishio, K.; Ishida, T.; Arioka, H.; Fukuoka, K.; Saijo, N. In vitro Enhancement of Antitumor Activity of a Water-soluble Duocarmycin Derivative, KW-2189, by Caffeine-mediated DNA-repair Inhibition in Human Lung Cancer Cells. Jpn. J. Cancer Res. 1997, 88, 1033-1037.
41. (a) Chidester, C. G.; Krueger, W. C.; Mizsak, S. A.; Duchamp, D. J.; Martin, D. G. The Structure of CC-1065, a Potent Antitumor Agent, and its Binding to DNA. J. Am. Chem. Soc. 1981, 103, 7629-7635.
42. (b) Warpehoski, M. A.; Gebnard, I.; Kelly, R. C.; Krueger, W. C.; Li, L. H.; McGovren, J. P.; Prairie, M. D.; Wicnienski, N.; Wierenga, W. Stereoelectronic Factors Influencing the Biological Activity and DNA Interaction of Synthetic Antitumor Agents Modeled on CC-1065. J. Med. Chem. 1988, 31, 590-603.
43. (c) Boger, D. L.; Tun, W. Role of the CC-1065 and Duocarmycin N2 Substituent: Validation of A Direct Relationship Between Solvolysis Chemical Stability and in vitro Biological Potency. J. Am. Chem. Soc. 1994, 116, 5523-5524.
44. Asai, A.; Nagamura, S.; Kobayashi, E.; Gomi, K.; Saito, H. Syntesis and Antitumor Activity of Novel Duocarmycin Derivatives. Bioorg. Med. Chem. Lett. 1996, 6, 1215-1220.
45. Nagamura, S.; Asai, A.; Amishiro, N.; Kobayashi, E.; Gomi, K.; Saito, H. Synthesis and Antitumor Activity of Duocrmycn Derivatives: A-ring Pyrrole Compounds Bearing Cinnamoyl Groups. J. Med. Chem. 1997, 40, 972-979.
46. (a) McGovren, J. P.; Clarke, G. L.; Pratt, E. A.; DeKoning, T. F. Preliminary Toxicity Studies with the DNA-binding Antibiotics, CC-1065. J. Antibiot. 1984, 37, 63-70.
47. (b) Warpehoski, M. A.; Harper, D. E.; Mitchel, M. A.; Monroe, T. J. Reversibility of the Covalent Reaction of CC-1065 and Analogues with DNA. Biochemistry 1992, 31, 2502-2508.
48. (c) Boger, D. L.; Yun, W. Reversibility of the Duocarmycin A and SA DNA Alkylation Reaction. J. Am. Chem. Soc. 1993, 115, 9872-9873.
49. (d) Asai, A.; Nagamura, S.; Saito, H.; Takahashi, I.; Nakano, H. The Reversible DNA-alkylating of Duocarmycin and its Analogues. Nucleic Acids Res. 1994, 22, 83-93.
50. CC-1065 analogues are promising candidates in clinical developments, (a) Li, L. H.; Kelly, R. C.; Warpehoski, M. A.; McGovren, J. P.; Gebhard, I.; Dekoning, T. F. Adozelesin, a Selected Lead among Cyclopropylpyrroloindole Analogues of the DNA-binding Antibiotic, CC-1065. Invest. New Drugs 1991, 9, 137-148.
51. (b) Li, L. H.; Dekoning, T. F.; Kelly, R. C.; Krueger, W. C.; McGovren, J. P.; Pudbury, G. E.; Petzold, G. L.; Wallace, T. L.; Ouding, R. J.; Prairie, M. D.; Gebhard, I. Cytotoxicity and Antitumor Activity of Carzelesin, A Prodrug Cyclopropylpyrroloindole Analogue. Cancer Res. 1992, 52, 4904-4913.
52. (c) Burns, H. A.; Dieras, V. C.; Tunca, M.; Earhart, R. H.; Eckardt, J. R.; Rodriguez, G. I.; Shaffer, D. S.; Fields, S. M.; Campbell, E.; Schaaf, L.; Kasunic, D.; Von Hoff, D. D. Phase I Study with the DNA Sequence-Specific Agent Adozelesin. Anti-Cancer Drugs 1997, 8, 588-596.
53. (d) Wolff, I.; Bench, K.; Beijnen, J. H.; Bruntsch, U.; Cavalli, F.; Jong, J.; Groot, Y.; Tellingen, O.; Wanders, J.; Sessa, C. Phase I Clinical and Pharmacokinetic Study of Carzelesin (U-80244) Given Daily for Five Consecutive Days. Clin. Cancer Res. 1996, 2, 1717-1723.
54. (e) Tellingen, O.; Punt, C. J. A.; Awada, A.; Wagener, D. J. T.; Piccart, M. J.; Groot, Y.; Schaaf, L. J.; Henrar, R. E. C.; Nooyen, W. J.; Beijnen, J. H. A Clinical Pharmacokinetics Study of Carzelesin Given by Short-Term Intravenous Infusion in a Phase I Study. Cancer Chemother. Pharmacol. 1998, 41, 377-384.
55. (f) Tellingen, O.; Nooijen, W. J.; Schaaf, L. J.; Valk, M.; Asperen, J.; Henrar, R. E. C.; Beijnen, J. H. Comparative Pharmacology of the Novel Cyclopropylpyrroloindole-Prodrug Carzelesin in Mice, Rats, and Humans. Cancer Res. 1998, 58, 2410-2416.
56. (a) Boger, D. L.; Bollinger, B.; Johnson, D. S. Examination of the Role of the Duocarmycin SA Methoxy Substituents: Identification of the Minimum, Fully Potent DNA Binding Subunit. Bioorg. Med. Chem. Lett. 1996, 6, 2207-2210.
57. (b) Boger, D. L.; Yun, W.; Han, N.; Johnson, D. S. CC-1065 CBI Analogues: An Example of Enhancement of DNA Alkylation Efficiency through Introduction of Stabilizing Electrostatic Interactions. Bioorg. Med. Chem. 1995, 3, 611-621.
58. (c) Boger, D. L.; Yun, W.; Han, N. 1,2,9,9a-Tetrahydrocyclopropa[c]benz[e]indol-4-one-(CBI) Analogues of CC-1065 and the Duocarmycins: Synthesis and Evaluation. Bioorg. Med. Chem. 1995, 3, 1429-1453.
59. (a) Lee, M.; Rhodes, A. L.; Wyatt, M. D.; D'Incalci, M.; Forrow, S.; Hartley, J. A. In Vitro Cytotoxicity of GC Sequence Directed Alkylating Agents Related to Distamycin. J. Med. Chem. 1993, 36, 863-870.
60. (b) Wyatt, M. D.; Lee, M.; Hartley, J. A. The Sequence Specificity of Alkylation for A Series of Benzoic Acid Mustard and Imidazole-containing Distamycin Analogues: The Importance of Local Sequence Conformation. Nucleic Acid Res. 1997, 25, 2359-2364.
61. Nishikawa, Y.; Shindo, T.; Ishii, K.; Nakamura, H.; Kon, T.; Uno, H. Acrylamide Derivatives as Antiallergic Agents. 2. Synthesis and Structure-activity Relationships of N-[4-(4-(diphenyl-methyl)-1-piperazinyl]butyl-3-(3-pyridyl)acryl Amides. J. Med. Chem. 1989, 32, 583-593.
62. (a) Heck, R. F.; Nolley, J. P. Palladium-catalyzed Vinylic Hydrogen Substitution Reaction with Aryl, Benzyl, and Styryl Halides. J. Org. Chem. 1972, 37, 2320-2322.
63. (b) Dieck, H. A.; Heck, R. F. Organophosphinepalladium Complexes as Catalysts for Vinylic Hydrogen Substitution Reactions. J. Am. Chem. Soc. 1974, 96, 1133-1136.
64. (b) Heck, R. F. Palladium-catalyzed Vinylation of Organic Halides. Org. React. 1982, 27, 345.
65. (c) Wada, A.; Yamamoto, J.; Hase, T.; Nagai, S.; Kanatomo, S. A. Convenient Synthesis of Methyl (E)-Pyrimidinyacrlates. Synthesis 1986, 7, 555-556.
66. (d) Wada, A.; Yamamoto, J.; Hase, T.; Nagai, S.; Kanatomo, S. A Convenient Synthesis Methyl (E)-Pyrimidinylacrylates. Synthesis 1986, 555-556.
67. (a) Jeffery, T. Palladium-catalyzed Vinylation of Organic Halides under Solid-liquid-Phase Transfer Conditions. J. Chem. Soc., Chem. Commun. 1984, 1287-1289.
68. (b) Jeffery, T. Highly Stereospecific Palladium-catalysed Vinylation of Vinylic Halides under Solid-liquid-Phase Transfer Conditions. Tetrahedron Lett. 1985, 26, 2667-2670.
69. Mukaiyama, T.; Usui, M.; Shimada, E.; Saigo, K. A Convenient Method for the Synthesis of Carboxylic Esters. Chem. Lett. 1975, 1045-1048.
70. (a) Nagamura, S.; Asai, A.; Kanda, Y.; Kobayashi, E.; Gomi, K.; Saito, H. Wagner-Meerwein Rearrangement of Duocarmycins. Chem. Pharm. Bull. 1996, 44, 933-939.
71. (b) Berner, D.; Cox, D. P.; Dahn, H. On the Migration of a HOOC Group in A Wagner-Meerwein Rearrangement in Superacid Solution: Proof by Double Labeling with Carbon-13. J. Am. Chem. Soc. 1982, 104, 2631-2632.
72. Geran, R. I.; Greenberg, N. H.; MacDonald, M. M.; Schumacher, A. M.; Abbott, B. J. Protocols for Screening Chemical Agents and Natural Products Against Animal Tumor and Other Biological Systems. Cancer Chemother. Rep. 1972, 3, 1-103.
73. Inaba, M.; Kobatashi, T.; Tashiro, T.; Sakurai, Y.; Maruo, K.; Ohnishi, Y.; Ueyama, Y.; Momura, T. Evaluation of Antitumor Activity in A Human Breast Tumor/Nude Mouse Model with A Special Emphasis on Treatment Dose. Cancer 1989, 64, 1577-1582.